Predictive Therapeutics is a clinical stage oncology company,with a focus on immunotherapy. We seek to acquire undervalued late stage assets for clinical development. Our goal is to unlock the potential of these promising cancer therapies in order to bring effective and safe drugs to patients.
Predictive Therapeutics is building a late-stage pipeline of differentiated cancer therapies
PT101 has been through Phase III clinical development with acceptable safety
Predictive Therapeutics, a Precision Medicine drug development company, has raised over $2,500,000 in Series A funding.
Biotech entrepreneur CEO, Dr. Asher Nathan, stated "I am extremely proud of the high quality senior management team we have been able to attract, and the faith that our Series A investors have placed in our ability to succeed. We are extremely excited by the steps we have been able to accomplish early in our existence."